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Abstract
The successful implementation of human embryonic stem cells (hESCs)-based technologies requires the production of
relevant numbers of well-characterized cells and their efficient long-term storage. In this study, cells were
microencapsulated in alginate to develop an integrated bioprocess for expansion and cryopreservation of pluripotent
hESCs. Different three-dimensional (3D) culture strategies were evaluated and compared, specifically, microencapsulation of
hESCs as: i) single cells, ii) aggregates and iii) immobilized on microcarriers. In order to establish a scalable bioprocess, hESC-
microcapsules were cultured in stirred tank bioreactors. The combination of microencapsulation and microcarrier
technology resulted in a highly efficient protocol for the production and storage of pluripotent hESCs. This strategy ensured
high expansion ratios (an approximately twenty-fold increase in cell concentration) and high cell recovery yields (.70%)
after cryopreservation. When compared with non-encapsulated cells, cell survival post-thawing demonstrated a three-fold
improvement without compromising hESC characteristics. Microencapsulation also improved the culture of hESC
aggregates by protecting cells from hydrodynamic shear stress, controlling aggregate size and maintaining cell
pluripotency for two weeks. This work establishes that microencapsulation technology may prove a powerful tool for
integrating the expansion and cryopreservation of pluripotent hESCs. The 3D culture strategy developed herein represents a
significant breakthrough towards the implementation of hESCs in clinical and industrial applications.
Citation: Serra M, Correia C, Malpique R, Brito C, Jensen J, et al. (2011) Microencapsulation Technology: A Powerful Tool for Integrating Expansion and
Cryopreservation of Human Embryonic Stem Cells. PLoS ONE 6(8): e23212. doi:10.1371/journal.pone.0023212
Editor: Christina Chan, Michigan State University, United States of America
Received February 4, 2011; Accepted July 14, 2011; Published August 5, 2011
Copyright:  2011 Serra et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by FCT Portugal (PTDC/BIO/72755/2006, SFRH/BD/42176/2007) and European Commission (Clinigene: LSHB-CT-2006-018933,
HYPERLAB: 223011). These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Janne Jensen
and Petter Bjorquist are employees of Cellartis AB and played a role in analysis and writing of the manuscript.
Competing Interests: Janne Jensen and Petter Bjorquist are employees of and hold equity in Cellartis AB. There are no patents, products in development or
marketed products to declare. This does not alter the authors9 adherence to all the PLoS ONE policies on sharing data and materials.
* E-mail: marques@itqb.unl.pt
. These authors contributed equally to this work.
Introduction
Human pluripotent stem cells, including embryonic stem cells
(hESCs) and induced pluripotent stem cells (hiPSCs) constitute an
exciting emerging field. The inherent capacity of these cells to
grow indefinitely (self-renewal) and to differentiate into any mature
cell of the human body (pluripotency) makes them extremely
attractive for regenerative medicine, tissue engineering, drug
discovery and toxicology [1]. However, the establishment of
effective and robust protocols for large-scale expansion, storage
and distribution of hESCs is imperative for the development of
high quality therapeutic products and/or functional screening
tools.
hESCs are routinely cultured in two-dimensional (2D) systems,
namely Petri dishes, well-plates and tissue culture flasks [2]. In
recent years, the inadequacy of conventional 2D culture systems in
mimicking the in vivo microenvironments of stem cell niches has
proven a constant shortcoming in both basic biology and tissue
engineering studies [3]. Despite the importance of cell-cell and
cell-matrix interactions in hESC cultivation, they have not yet
been properly addressed in these systems. In addition, the inherent
variability, lack of environmental control and low production
yields associated with these culturing approaches are the main
drawbacks hampering the development of efficient, scalable and
cost-effective stem cell expansion processes (reviewed in [4]). The
low cell recovery yields and the high rates of uncontrolled
differentiation obtained after cryopreservation [5] also limit the
use of the 2-D systems in clinical and/or industrial applications.
Much effort has been invested in the development of more
efficient hESC culture systems, namely by combining a strategy for
3D cell organization with a bioreactor-based system where
scalability, straightforward operation and homogeneous culture
environment are guaranteed [6,7]. Recent studies have shown the
successful use of stirred tank bioreactors (spinner vessels and
environmentally controlled stirred tank bioreactors) for expanding
hESCs as aggregates or immobilizing them on microcarriers
[6,7,8]. From a clinical/industrial perspective, these systems still
require further improvements in order to increase cell expansion
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vation protocols. In fact, stirred culture vessels often apply
mechanical forces (mixing and occasionally perfusion) to the cells,
which may ultimately compromise cell viability, morphology, gene
expression and differentiation potential [9]. The excessive
aggregate/microcarrier clumping observed during culture is
another concern since it may lead to the formation of necrotic
centers and/or promote spontaneous differentiation, reducing cell
expansion yields. Moreover, the development of effective cryo-
preservation protocols capable of ensuring efficient cell storage
and transportation after large-scale expansion is still lacking.
Although Nie et al reported a new method for the cryopreservation
of hESCs adherent on microcarriers [10], this protocol needs
further optimization in order to remove animal feeder cells and
improve cell attachment/survival after thawing.
Cell microencapsulation technology is an attractive approach
for overcoming the bioprocess challenges mentioned above since it
provides cell protection from hydrodynamic shear and prevents
excessive aggregate agglomeration while allowing for the efficient
diffusion of nutrients, growth factors and gases through the
microcapsule matrix [11]. Several hydrogels have been used in
hESC culture including alginate [12], poly(lactic-co-glycolic acid)/
poly(l-lactic acid) scaffolds [13], agarose [14], chitosan [15] and
hyaluronic acid [16]. Alginate is the most common encapsulation
material due to its intrinsic properties including biocompatibility,
biosafety and permeability [17]. The production of alginate cell-
microcapsules can be performed under safe and physiological
conditions (e.g. physiological temperature and pH, use of isotonic
solutions instead of cytotoxic solvents) [18] and using good
manufacturing practice (GMP) guidelines [19], a fact which
potentiates the use of this technology in cell-based therapies.
Indeed, the great potential of alginate microcapsules for
transplantation of Langerhans’ islets and other factor-secreting
cells and tissues has already been reported [20,21].
Cell microencapsulation in alginate has been adopted by our
group and others to improve the viability and functionality of
primary hepatocytes [22,23] and to enhance the differentiation of
stem/progenitor cells into different cell types in bioreactors
[24,25,26,27,28]. In addition, we recently demonstrated that cell
encapsulation in alginate is a valuable strategy for improving cell
viability and the integrity of cell monolayers and neurospheres
after freeze/thawing, since cells are protected against mechanical
damages during ice crystallization and the risk of disrupting cell-
cell and cell-matrix contacts are reduced through immobilization
within the hydrogel [29,30]. Despite such success in many (stem)
cell types, studies describing the microencapsulation of hESCs are
still limited [12,25,31].
This paper reports the first efficient integrated bioprocess for the
expansion and cryopreservation of hESCs using cell microencap-
sulation in alginate. Different strategies were evaluated and
compared including microencapsulation of i) single cells, ii) cell
aggregates and iii) cells immobilized on microcarriers, since each
approach allows for different cell-cell/matrix interactions. Micro-
capsules containing hESCs were cultured in stirred tank
bioreactors (spinner vessels) and, after expansion, cryopreserved
in cryovials, in order to develop a scalable and straightforward
bioprocess.
Materials and Methods
hESCs culture on feeder layer
hESCs (SCED
TM461, Cellartis AB, Go ¨teborg, Sweden) were
routinely propagated as colonies in static systems (6 well-plates) on
a feeder layer of human foreskin fibroblasts (hFF, ATCC
collection), inactivated with mitomycin C (Sigma-Aldrich, Stein-
heim, Germany), in DMEM-KO culture medium (Knockout
TM-
DMEM supplemented with 20% (v/v) Knockout-Serum Replace-
ment (KO-SR), 1% (v/v) MEM non-essential amino acids (MEM-
NEAA), 0.1 mM 2-mercaptoethanol, 2 mM Glutamax, 1% (v/v)
Pen/Strep, 0.5% (v/v) Gentamycin (all from Invitrogen, Paisley,
UK)) and 10 ng/mL basic fibroblast growth factor bFGF (Neuilly-
Sur-Seine, France, Peprotech), as previously described [2]. Every
10–12 days, i.e. when hESC colonies covered approximately 75–
85% of the surface area of the culture well, they were digested with
TrypLE
TM Select (Invitrogen, Paisley, UK) for 6–8 minutes, and
the single cell suspension was transferred to freshly inactivated hFF
feeders (at splitting ratios between 1:4 and 1:24). The culture
medium was replaced every 1–3 days.
Preparation of mEFs conditioned medium
For the production of conditioned medium (mEF-CM), mouse
embryonic fibroblasts (mEFs, Millipore, Billerica, MA, USA) were
mitotically inactivated and replated on gelatin-coated T-flasks
(Nunc, Roskilde, Denmark) at 5.5610
4 cell/cm
2 in DMEM-KO
medium without bFGF (0.5 mL/cm
2). Briefly, inactivated mEFs
were cultured at 37uC with 5% (v/v) CO2 (in air) and conditioned
media were collected daily for a total of 10 days per batch. Before
feeding to hESC cultures, mEF-CM was filtered and supplement-
ed with 10 ng/mL bFGF and 0.1 nM Rapamycin (Sigma,
Steinheim, Germany).
Microencapsulation of hESCs
Alginate. Ultra Pure MVG alginate (UP MVG NovaMatrix,
Pronova Biomedical, Oslo, Norway) was prepared at a
concentration of 1.1% (w/v) in 0.9% (w/v) NaCl solution [31].
Microcapsule formation. Microcapsules were prepared by
passing the alginate-cell mixture using a 1 mL syringe through an
air-jet generator as described elsewhere [22,23,32] at an air flow
rate of 2–3.5 L/min and an air pressure of 1 bar. These
encapsulation conditions yielded microcapsules with a diameter
of approximately 500–700 mm. For cross-linkage of the UP MVG
alginate, a 100 mM CaCl2/10 mM HEPES solution adjusted to
pH 7.4 was used. Alginate microcapsules were washed twice with
0.9% (w/v) NaCl solution and once with DMEM-KO medium
before being transferred to culture systems.
Alginate microcapsules dissolution. Ca
2+-UP MVG
alginate was dissolved by incubating the microcapsules with a
chelating solution (50 mM EDTA and 10 mM HEPES in PBS) for
5 min at 37uC [31].Cells were washed twice with PBS and
incubated with culture medium until further analysis.
Three-dimensional (3D) hESC cultures
Figure 1 describes the main steps of the 3D culture strategies
developed.
Encapsulation of single cells. Before detachment from 2D
static cultures, hESCs colonies were pre-treated for 1 h with 5 mM
Y-27632, a selective Rho kinase (ROCK) inhibitor (ROCKi,
Calbiochem Nottingham, UK). The single cell suspension,
obtained after dissociating the colonies with TrypLE Select, was
immediately encapsulated at different concentrations in alginate
(0.75, 2 and 3610
6 cell/mL alginate). hESCs-microcapsules were
then inoculated into 125 mL Erlenmeyer (Corning, Corning, NY,
USA) and cultured in 15 mL mEF-CM supplemented with 10 mM
ROCKi, at 37uC and 5% CO2 in an orbital shaker with an
agitation of 70 rpm. In all conditions tested, cells were inoculated
at 1.5610
5 cell/mL.
Encapsulation of hESC aggregates. hESCs were
dissociated from the 2D static cultures and inoculated as single
hESC Culture and Cryopreservation in Microcapsules
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5 cell/mL into Erlenmeyer (Corning, Corning, NY,
USA). Cells were cultured in 50 mL mEF-CM supplemented with
10 mM ROCKi, at 37uC and 5% CO2, using an orbital agitation
of 70 rpm. Encapsulation was performed at day 2; aggregates were
pre-treated with 5 mM ROCKi for 1 h and then transferred to
15 mL tubes to allow them to deposit and be removed from the
culture medium. After the addition of alginate, aggregates were
encapsulated, transferred to 125 mL spinner vessels (Wheaton,
Techne, NJ, USA) equipped with paddle impellers and cultured in
100 mL of mEF-CM at 45 rpm for an additional 16 days. The
culture medium was partially replaced three times a week by
stopping agitation (to induce microcapsule deposition), removing
50% of the medium and feeding with 50% of fresh medium.
Cultures of non-encapsulated aggregates were also performed in
parallel and used for control purposes. Both cultures were
monitored for cell viability, metabolic activity, aggregate size,
concentration and composition throughout the experiments. For
flow cytometry analysis, aggregates were transferred to gelatin
coated surfaces, in mEF-CM, where cells were able to migrate.
After 2–3 days, cells were dissociated using TrypLE Select and
processed for flow cytometry analysis using the protocol described
below.
Encapsulation of hESCs immobilized on microca-
rriers. hESCs were inoculated at 4.5610
5 cell/mL into
125 mL spinner vessels with paddle impellers containing
Cytodex3
TMmicrocarriers (2 g/L, GE Healthcare, Uppsala,
Sweden). The microcarriers were prepared and sterilized
according to the manufacture’s recommendation and coated
with Matrigel (BD Biosciences, Bedford, MS, USA) as described in
the literature [7]. Cells were cultured in 25 mL of mEF-CM
supplemented with 10 mM ROCKi, and the spinner vessels were
placed inside an incubator at 37uC, 5% CO2 under intermittent
stirring. After 6 h, fresh mEF-CM was added to the cultures and
the agitation rate was set to 24 rpm. By day 3, more media was
added for a final volume of 100 mL. The encapsulation was
performed at day 6; empty microcarriers (1 or 2 g/L) coated with
Matrigel were added to the cultures 1 h before encapsulation.
During this period, cultures were treated with 5 mM ROCKi.
After encapsulation, hESCs were transferred to spinner vessels and
cultured in the same conditions for an additional 13 days. Fifty
Figure 1. Main steps of the microencapsulated 3D culture strategies developed for expansion and cryopreservation of hESCs.
doi:10.1371/journal.pone.0023212.g001
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encapsulated cells-microcarriers were also performed and run in
parallel as a control. Both cultures were monitored for cell
concentration, viability and culture composition over time.
At the end of the expansion process of both cell aggregates and
hESC-microcarrier cultures, microcapsules were dissolved,using
the protocol described above (section- microencapsulation of
hESC),and hESC clumps were dissociated and plated on top of a
monolayer of inactivated hFF to further assess cell pluripotency.
Cell cryopreservation
Cultures of non-encapsulated and encapsulated hESCs were
harvested from the spinner vessels and cryopreserved using the
slow freezing rate method [30]. The hESC-microcarriers and
hESC-aggregates were collected at day 13 and 14 of culture,
respectively (Figure 1), and all samples were pre-treated with 5 mM
ROCKi for 1 hour before cryopreservation.
Freezing. At freezing, after the deposition of the
microcapsules, the culture medium was removed and the
cryopreservation medium (90% KO-SR, 10% (v/v) DMSO
(Sigma, Steinheim, Germany), 5 mM ROCKi) was added. Cell
suspensions were then transferred to cryovials (Nunc, Roskilde,
Denmark) (1 mL/vial). The cells were allowed to equilibrate in the
cryopreservation medium for 20 minutes at 4uC. Samples were
frozen to 280uC in an isopropanol-based freezing system, (‘‘Mr.
Frosty’’, Nalgene, NY, USA) at a rate of 1uC per minute, and
stored in the gas phase of a liquid nitrogen reservoir until thawing.
Thawing. Following storage, cells were quickly thawed by
placing the cryovials in a 37uC water bath; a stepwise dilution (1:1,
1:2, 1:4) in mEF-CM was performed immediately afterwards in
order to dilute the DMSO while reducing osmotic shock [30].
Cells-microcapsules were transferred to Petri-dishes and cultured
for 9 days in mEF-CM supplemented with 5 mM of ROCKi.
Media exchange was performed daily. At day 9, microcapsules
were dissolved and hESC clumps were dissociated with TrypLE
Select; hESCs were transferred to a monolayer of inactivated hFF
and maintained in culture for several passages for post-thaw
studies of growth and pluripotency.
Assessment of hESC survival after thawing. The
percentage of hESCs survival/recovery after thawing was
determined by calculating the ratio between the number of
viable hESCs after cryopreservation and the number of initially
frozen viable hESCs, counted using a Fuchs-Rosenthal
haemocytometer chamber (Brand, Wertheim, Germany) and the
Trypan Blue (Invitrogen, Paisley, UK) exclusion method.
Evaluation of cell viability
Three methods were used to estimate cell viability.
Cell membrane integrity assay. The qualitative assessment
of the cell plasma membrane integrity during culture was
performed using the enzyme substrate fluorescein diacetate
(FDA; Sigma-Aldrich, Steinheim, Germany) and the DNA-dye
propidium iodide (PI; Sigma-Aldrich, Steinheim, Germany) as
described in the literature [7]. Briefly, cells/microcapsules were
incubated with 20 mg/mL FDA and 10 mg/mL PI in PBS for 2–
5 min and then observed using fluorescence microscopy (Leica
Microsystems GmbH, Wetzlar, Germany).
Trypan Blue exclusion method. The total number of viable
cells was determined by counting the colorless cells in a Fuchs-
Rosenthal haemocytometer chamber after incubation with
Trypan Blue dye (0.1% (v/v) in PBS).
Lactate dehydrogenase (LDH) activity. LDH activity from
the culture supernatant was determined by monitoring the rate of
oxidation of NADH to NAD
+ coupled with the reduction of
pyruvate to lactate at 340 nm. The specific rate of LDH release
(qLDH) was calculated for each time interval using the following
equation: qLDH=(DLDH)/( Dt6DXv), where DLDH is the
change in LDH activity over the time period Dt, and DXv is the
average of the total cell number during the same period. The
cumulative value qLDHcum was estimated by qLDHcum i+1
=q LDHi+qLDH i+1.
Evaluation of metabolic activity
AlamarBlue
TM assay. hESCs metabolic activity was
assessed using the metabolic indicator alamarBlue according to
the manufacture’s recommendation (Paisley, UK, Invitrogen).
Briefly, 2 mL of hESC culture were incubated overnight with fresh
medium containing 10% (v/v) alamarBlue. Fluorescence was
measured in 96-well plates using a microwell plate fluorescence
reader (FluoroMax-4, Horiba JobinYvon).
Evaluation of cell growth
Apparent growth rate (mapp). mapp was estimated using a
simple first-order kinetic model for cell expansion: dX/dt=mX,
where t (day) is the culture time and X (cell) is the value of viable
cells for a specific t. The value of m was estimated using this model
applied to the slope of the curves during the exponential phase.
Expansion ratio or fold increase (FI) in cell
concentration. FI was evaluated based on the ratio XMAX/
X0, where XMAX is the peak of cell density (cell/mL) and X0 is the
lowest cell density (cell/mL).
Characterization of hESCs
For all culture samples, microcapsules were dissolved prior to
analysis using the protocol described above (section- microencap-
sulation of hESC). The undifferentiated status of hESCs was
evaluated by analyzing the activity of alkaline phosphatase (AP)
and by detecting the expression of specific stem cell and
pluripotency markers using immunocytochemistry and flow
cytometry analysis.
Alkaline Phosphatase (AP) staining. Cultures were stained
using an AP activity detection kit (Millipore, Billerica, MA, USA)
according to the manufacturer’s instructions and observed using
an inverted phase contrast microscope (Leica Microsystems
GmbH).
Immunocytochemistry. Cultures of hESC were fixed in 4%
(w/v) paraformaldehyde (PFA) in PBS for 20 minutes,
permeabilized (only for detection of intracellular markers Oct-4
and Nanog) for 5 minutes in 0.1% (w/v) Triton X-100 (Sigma-
Aldrich, Steinheim, Germany) in PBS and subsequently incubated
with primary antibody overnight at 4uC. Cells were washed three
times in PBS and then incubated with secondary antibodies during
1 h at room temperature in the dark. After three washing steps
with PBS, cell nuclei were counterstained with 4,6-diamidino-2-
phenylindole (DAPI, Sigma-Aldrich, Steinheim, Germany). Cells
were visualized using spinning disk confocal (Nikon Eclipse Ti-E,
confocal scanner: Yokogawa CSU-x1) and inverted (Leica
Microsystems GmbH) fluorescence microscopy. In samples of
hESC aggregates, an additional permeabilization step was
performed before the addition of primary antibodies; cells were
incubated with 0.2% fish skin gelatin and 0.1% TX-100 in PBS for
2 h at room temperature. Primary antibodies used were: Tra-1-60,
Tra-1-81, Oct-4 (all from Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and Nanog (Millipore). Secondary antibodies used
were: goat anti-mouse IgM-AlexaFluor488 and goat anti-mouse
IgG-AlexaFluor 488 (all from Invitrogen, Paisley, UK).
Flow cytometry. Cell clumps were dissociated with TrypLE
Select and the single cell suspension was re-suspended in washing
hESC Culture and Cryopreservation in Microcapsules
PLoS ONE | www.plosone.org 4 August 2011 | Volume 6 | Issue 8 | e23212buffer (WB) solution (5% (v/v) FBS in PBS). After two washing
steps, cells were incubated with primary antibody for 1 h at 4uC,
washed three times in WB and then incubated with the secondary
antibody for additional 30 min at 4uC. After 2 washing steps with
WB, cells were analyzed in a CyFlowH space (PartecGmbH,
Mu ¨nster, Germany) instrument as reported elsewhere [16]. Ten
thousand events were registered per sample. Primary antibodies
used were: Tra-1-60, SSEA-4, SSEA-1 and isotype control
antibodies (all Santa Cruz Biotechnology, Santa Cruz, CA,
USA) and hES-Cellect
TM (Cellartis AB, Go ¨teborg, Sweden).
Secondary antibodies used were: goat anti-mouse IgM-
AlexaFluor488 and goat anti-mouse IgG-AlexaFluor 488 (all
from Invitrogen, Paisley, UK).
In vitro pluripotency
The cell pluripotency was evaluated in vitro via embryoid body
(EB) formation and spontaneous differentiation. Microcapsules
were dissolved as described above and hESCs dissociated,
transferred to non-adherent Petri dishes (5610
5 cell/mL) and
cultured in suspension for 1 week in DMEM-KO medium without
bFGF. EBs formed during this time were harvested and cultured
in gelatin-coated plates for a further 2 weeks (the medium was
changed three times a week). Differentiated cells were identified
using immunocytochemistry as described above. Primary antibod-
ies used were: a-smooth muscle actin (DAKO, Glostrup, Den-
mark), Forkhead box A2 (Santa Cruz Biotechnology, Santa Cruz,
CA, USA) and b tubulin type III (Chemicon, Temecula, CA,
USA). Secondary antibodies used were: goat anti-mouse IgG-
AlexaFluor488 and donkey anti-goat IgG-AlexaFluor594 (all from
Invitrogen, Paisley, UK).
Data analysis and statistics
All data presented show n.2 replicates. Error bars denote the
standard deviation of the mean. For membrane integrity and
immunofluorescence microscopy, representative photographs are
depicted.
Statistical difference between encapsulated and non-encapsu-
lated cultures was assessed using single factor ANOVA. A 95%
confidence level was considered to be statistically significant.
Results
Results previously reported by our group and others demon-
strate that it is possible to expand hESCs as aggregates or when
immobilized on microcarriers in stirred tank bioreactors [6,7,8].
Attempting to further increase the cell expansion yields, different
3D cell microencapsulation strategies were evaluated. The most
promising strategies were selected to assess the impact of
microencapsulation on cell cryopreservation, with the goal of
implementing an integrated bioprocess for the robust expansion
and storage of pluripotent hESCs. In this work, calcium 1.1% (w/
v) UP MVG alginate microcapsules were used since the properties
of this matrix fulfill the main requisites (permeability, stability and
elasticity) for supporting an efficient hESC culture [31].
Expansion of microencapsulated hESCs as single cells
We first investigated the hypothesis of expanding single hESCs
in alginate microcapsules. Cells were encapsulated at different
concentrations, 0.75, 2 and 3610
6 cell/mL alginate, and
inoculated at 1.5610
5 cell/mL in stirred culture systems. For all
conditions tested, cell viability decreased gradually from approx-
imately 95% to 5% after 7 days of cultivation (Figure S1). When a
higher cell concentration was used (3610
6 cell/mL alginate),
viable cell aggregates were observed in culture from day 7
onwards, indicating that some cells remained viable and
proliferated. However the percentage of populated microcapsules
was very low (,10%, data not shown). These results indicate that
the microencapsulation of single cells is not a suitable strategy for
expanding hESCs.
Expansion of microencapsulated hESC aggregates in
stirred tank bioreactors
For the second strategy, hESCs were induced to form small cell
aggregates after single cell enzymatic dissociation (Figure 1). By
day 2, aggregates ranging from 30–100 mm were encapsulated to
generate approximately 1 aggregate per microcapsule, and
transferred to spinner vessels.
The results show that the microencapsulation of aggregates
enhanced the culture performance of hESCs as compared to the
microencapsulation of single cells. Aggregates of hESC presented
high cell viability and a spherical shape during culture time
(Figure 2A). After 2 weeks, an increase in aggregate size (5-fold,
Table 1, Figure 2D) and in metabolic activity (2-fold, Figure 2B
and Table 1) was observed, indicating that hESCs proliferated
inside alginate microcapsules. Overall, a significant improvement
in cell viability and metabolic activity was obtained as compared to
non-encapsulated cultures (P,0.05) where aggregates clumped
together and formed large (.1 mm in size) irregular structures
with necrotic centers (Figure 2A). In fact, the pronounced decrease
in metabolic activity and the high values of cumulative LDH
release confirm that the culture of non-encapsulated hESC
aggregates in spinner vessels resulted in substantial cell death
(Figure 2B, C).
Aggregates collected after microcapsule dissolution maintained
their integrity and high cell viability (not shown), thus ensuring
efficient cell characterization. The results show that hESCs
expanded as encapsulated 3D aggregates retained their undiffer-
entiated phenotype during 2 weeks of culture in spinner vessels, as
evaluated by immunofluorescence microscopy and flow cytometry
(Figure 2E–G). By day 7, the percentages of SSEA-4 and TRA-1-
60 positive cells were high (94.6% and 89.2%, respectively),
indicating that most cells kept an undifferentiated character
(Figure 2E–G). Additionally, for all culture time points the
percentages of SSEA-1 positive cells were always below 10%
(Figure 2E). At day 18, a significant decrease in SSEA-4 and TRA-
1-60 positive cells was observed (Figure 2E); the presence of EB-
like structures (aggregates with irregular shape and cystic cavities)
at this time (data not shown), suggests that hESCs had started to
differentiate.
After alginate dissolution, microencapsulated hESC aggregates
expanded in the bioreactor were able to form undifferentiated
colonies on top of a monolayer of inactivated hFF (Figure 2H).
Moreover, these cells differentiated spontaneously in vitro, via EB
formation, into cells from the three germ layers (Figure 2I),
confirming that they maintained their pluripotent potential.
Expansion of encapsulated hESC immobilized on
microcarriers in stirred tank bioreactors
For the third strategy, hESCs were immobilized on Matrigel-
coated Cytodex 3 microcarriers (3 g/L) [7] and encapsulated in
alginate. First, the microencapsulation step was tested at different
culture time points: 8 h (day 0), and days 1, 3 and 6. Day 6 was
selected since it allowed a higher percentage of microcarriers and
microcapsule colonization (data not shown). Preliminary experi-
ments also demonstrated that the addition of empty supports (1 g/
L) on cell-microcarrier cultures (cells immobilized on micro-
carriers, 2 g/L, yielding a final concentration of 3 g/L) immedi-
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PLoS ONE | www.plosone.org 5 August 2011 | Volume 6 | Issue 8 | e23212Figure 2. Effect of alginate microencapsulation on the expansion of hESC as aggregates. hESC aggregates were encapsulatedatday2 and
cultured in spinner vessels. (A) Phase contrast and fluorescence images of encapsulated and non-encapsulated cultures at days 3, 7 and 9. Viability of
hESCaggregatesassessedbystainingwithfluoresceinediacetate(FDA-livecells, green) andpropidiumiodide (PI-deadcells,red). Scalebar:100 mm.(B–
C) Cell growth performance of both encapsulated (purple) and non-encapsulated (grey) cultures. (B) Metabolic activity measured by alamarBlue test on
theday after microencapsulation (day 3)andatday15. Error bars denote SDof 3 measurements. **indicatessignificantdifference (P,0.05)inmetabolic
activity by one-way ANOVA analysis. (C) Cumulative values of specific rates of LDH release overtime. Error bars denote SD of 3 measurements. (D)
Aggregate size of encapsulated cultures at days 2, 4, 7 and 15 of culture. Error bars denote SD of 10 measurements. (E–I) Characterization of
encapsulated hESC aggregates expandedin spinnervessels.(E) Percentage ofSSEA-4, TRA-1-60andSSEA-1positivecells atdays7 (purplebars), 14(pink
stripes bars) and 21 (grey stripes bars). Error bars represent SD of 2 measurements. (F) Flow cytometry analysis of SSEA-4 and TRA-1-60 positive cells at
day 7 of culture. (G) Confocal images of aggregates labeled for Oct-4 and TRA-1-60 at day 16 of 3D culture. Scale bar: 50 mm. (F–G) Flow cytometry
analysis of the expanded population (H) Immunofluorescence images of Oct-4 and TRA-1-60 labeling and phase contrast pictures of alkaline
phosphatase (AP) activity, staining after expansion (2D culture). Nuclei were labeled with DAPI (blue). Scale bars: immunofluorescence images - 200 mm,
AP image 21m m .( I) In vitro pluripotency analysis. Microcapsules were dissolved and hESCs were transferred to a monolayer of inactivated hFF. At
confluence, colonies were dissociated and hESCs were able to form embryoid bodies (EBs) in non-adherent conditions and differentiated into cells from
all three germ layers. Fluorescence images of differentiated cultures labeled for a–SMA (a smooth muscle actin, mesoderm), FOX-A2 (Forkheadbox A2,
endoderm) and bIII-Tub (b tubulin type III, ectoderm). Nuclei were stained with DAPI (blue). Scale bar: 100 mm.
doi:10.1371/journal.pone.0023212.g002
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the addition of empty and freshly coated supports promoted cell
migration and further proliferation inside the capsule, ultimately
increasing the number of populated microcapsules and cell yields
(data not shown).
Encapsulated hESCs immobilized on microcarriers were
cultured for 19 days in spinner vessels (Figure 1). The results
show that the microencapsulation of cell-microcarriers in alginate
markedly enhanced cell viability and expansion when compared to
non-encapsulated cultures (Table 1, Figure 3A, B). By day 19, the
fold increase in cell concentration was higher in encapsulated
(10.760.8) than in non-encapsulated (7.760.2) cultures, which
supports the hypothesis that alginate microcapsules protect the
cells from hydrodynamic shear stress, enhancing cell migration
and further proliferation on microcarriers. Moreover, no differ-
ences were observed in the apparent growth rates (Table 1),
indicating that the alginate matrix did not compromise the hESCs
proliferation potential.
To further improve cell expansion yields, we increased the
concentration of microcarriers: 2 g/L of empty supports were
added before microencapsulation, yielding a final concentration of
4 g/L. The increase in available cell growth surface area
contributed to augmenting the final cell concentration (2.9610
6
cell/mL corresponding to a 19.261.8 ratio of expansion, Table 1).
Within microcapsules, cells migrated and colonized most of the
microcarriers,with totalviablecellsincreasingovertime(Figure 3C).
It is important to point out that, using these conditions, the
exponential growth phase was prolonged until day 19 (Figure 3A).
The culture was aborted at this time because cell overgrowth was
observed in some microcapsules (data not shown).
After expansion as encapsulated cell-microcarrier aggregates,
hESCs retained their undifferentiated phenotype and pluripotency
markers (Figure 3D–F). When compared to non-encapsulated
cultures, results were very similar with the exception of TRA-1-60
where higher levels of positive cells were registered in the
encapsulated cultures (Figure 3D). The percentage of SSEA-1
positive cells was higher in non-encapsulated (13.060.4%) than in
encapsulated cultures (7.860.3%) (Figure 3E), indicating that, at
the end of the expansion process, more cells in an early
differentiated state were presented in the former case.
Encapsulated cells maintained the capacity to form undifferen-
tiated colonies in 2D standard monolayer systems (Figure 3G) and
presented in vitro pluripotency; cells were able to form EBs and
spontaneously differentiate into cells from the three embryonic
germ layers (Figure 3H).
Cryopreservation of hESCs using 3D microencapsulated
culture strategies
Since hESCs can be successfully expanded in microcapsules as
cell aggregates or immobilized on microcarrier surfaces, we
evaluated the possibility of cryopreserving these 3D structures and
investigated whether microencapsulation in alginate would improve
cell viability and survival ratios. Cells were harvested from the
bioreactor cultures at specific culture time points (day 13 and 14 for
hESCs-microcarriers and aggregate cultures, respectively) (Figure 1)
and cryopreserved using the slow rate freezing protocol.
Results showed that in aggregate culture, alginate microencap-
sulation did not prevent cell death immediately after thawing
(Figure 4A). On the contrary, microencapsulated hESCs immo-
bilized on microcarriers presented high cell viabilities and cell
Table 1. Expansion and cryopreservation of encapsulated and non-encapsulated hESC cultures.
Culture Strategy hESC aggregates
Alginate Microencapsulation No Yes
EXPANSION
Fold increase in metabolic activity (2weeks) 0 2.460.2
Initial aggregate size (day 2) (mm) 53616 53616
Final aggregate size (day 15) (mm) -2 5 7 661
CRYOPRESERVATION
% cell survival 0% 0%
Culture Strategy hESCs immobilized on microcarriers
Alginate Microencapsulation No Yes Yes
Microcarrier Concentration 3 g/L 3 g/L 4 g/L
EXPANSION
Initial cell concentration
(610
5 cell/mL)
1.760.3 1.860.1 1.560.6
Maximum cell concentration
(610
5 cell/mL)
12.760.5 19.062.4 28.263.8
Expansion ratio/Fold increase related to initial cell concentration 7.760.2 10.760.8 19.261.8
Apparent growth rate, mapp (day
21) 0.1460.03
(R
2=0.99)
0.1560.07
(R
2=0.99)
0.1660.02
(R
2=0.94)
CRYOPRESERVATION
% cell survival:
Immediately after thawing 55.764.6% 103.768.8% -
1 day after thawing 24.962.8% 71.065.0% -
doi:10.1371/journal.pone.0023212.t001
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PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23212Figure 3. Effect of alginate microencapsulation on the expansion of hESCs immobilized on microcarriers. hESCs were immobilized on
Matrigel-coated microcarriers (2 g/L) and encapsulated at day 6. Before microencapsulation empty coated microcarriers (1 g/L and 2 g/L) were
added. Non-encapsulated (grey) and encapsulated hESCs using 3 g/L (purple) and 4 g/L (pink) of microcarriers were cultured in spinner vessels. (A)
Growth curve expressed in terms of cell number per volume of medium. Error bars denote SD of 3 measurements. (B) Cumulative values of specific
rates of LDH release during culture time. Error bars denote SD of 3 measurements. (C) Phase contrast and fluorescence images of encapsulated hESC
cultures (on 4 g/L microcarriers) at days 7, 12 and 14. Viability analysis of cultures stained with fluoresceine diacetate (FDA-live cells, green) and
propidium iodide (PI- dead cells, red). Scale bar: 200 mm. (D–H) Characterization of encapsulated hESCs immobilized on microcarriers expanded in
spinner vessels: (D) Flow cytometry analysis of non-encapsulated (grey bars) and encapsulated (purple bars) hESCs immobilized on microcarriers at
the end of the expansion process - percentage of SSEA-4, TRA-1-60 and hES-CellectTM (hES) and (E) SSEA-1 positive cells in relation to the 2D control
culture; error bars represent SD of 2 measurements. (F) Confocal images of Oct-4, TRA-1-60, TRA-1-81 and NANOG labeling and phase contrast
pictures of alkaline phosphatase (AP) activity at day 19 of encapsulated 3D culture. Nuclei were labeled with DAPI (blue). Scale bar: 200 mm, merge
and phase contrast images 100 mm. (G) Immunofluorescence images of Oct-4, TRA-1-60, TRA-1-81 and NANOG labeling after expansion (2D culture).
Nuclei were labeled with DAPI (blue). Scale bars: 200 mm and 1 mm for immunofluorescence and phase contrast images, respectively. (H) In vitro
pluripotency analysis. Microcapsules were dissolved and hESCs were detached from the microcarriers and transferred to a monolayer of inactivated
hFF. At confluence, colonies were dissociated and hESCs were able to form embryoid bodies (EBs) in non-adherent conditions and differentiated into
cells from all three germ layers. Fluorescence images of differentiated cultures labeled for a–SMA (a smooth muscle actin, mesoderm), FOX-A2
(Forkheadbox A2, endoderm) and bIII-Tub (b tubulin type III, ectoderm). Nuclei were stained with DAPI (blue). Scale bar: 100 mm.
doi:10.1371/journal.pone.0023212.g003
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efficient for the cryopreservation of hESCs as compared to their
non-encapsulated culture counterpart; immediately and one day
after thawing, the percentage of cell survival was significantly
higher in encapsulated (day 0=103.768.8%, day 1=71.065.0%)
than in non-encapsulated cells (day 0=55.764.6%, day
1=24.962.8%) (P,0.05) (Figure 4B, Table 1). Although some
cell death occurred in the first days post-thawing, microencapsu-
lated hESCs immobilized on microcarriers more quickly recovered
their proliferative and metabolic activity (Figure 4C). In non-
encapsulated cultures, cells were prone to detach from the
microcarriers after thawing resulting in pronounced levels of cell
death (Figure 4A); additionally, cells did not re-establish their
metabolic activity and the values of LDH were higher than in
encapsulated cultures at all time points (Figure 4C–D).
To investigate whether microencapsulated hESCs immobilized
on microcarriers maintained their pluripotent characteristics after
cryopreservation, cells were characterized 9 days post-thawing and
during 5 additional passages on top of inactivated hFF
monolayers. The results confirmed that hESCs maintained their
Figure 4. Post-thawing survival of non-encapsulated and encapsulated hESCs. Non-encapsulated and encapsulated hESCs were
cryopreserved as aggregates or immobilized on microcarrier using a slow freeze rate method. (A) Phase contrast and fluorescence images of
cryopreserved hESC immediately, 1, 3 and 7 days after thawing. Viability analysis of hESCs stained with fluoresceinediacetate (FDA-live cells, green)
and propidium iodide (PI- dead cells, red). Scale bar: 200 mm. (B–D) Post-thawing characterization of non-encapsulated (grey) and encapsulated
(purple) hESCs immobilized on microcarriers. (B) Percentage of cell survival immediately and one day after thawing. Error bars denote SD of 3
measurements. (C) Metabolic activity measured by alamarBlue test before cryopreservation and 1 and 9 days after thawing. Error bars denote SD of 4
measurements. ** indicates significant difference (P,0.05) in metabolic activity by one-way ANOVA. (D) Cumulative values of specific rates of LDH
release of cryopreserved hESCs after thawing. Error bars denote SD of 3 measurements.
doi:10.1371/journal.pone.0023212.g004
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and the ability to differentiate in vitro into cells from the three germ
layers (Figure 5D).
Discussion
Efficient culture strategies are urgently needed to accelerate the
transition of hESCs to clinical and industrial applications. This
study intended to develop an integrated bioprocess for the
expansion and cryopreservation of pluripotent hESCs; our
approach consisted of designing 3D culture strategies using cell
microencapsulation in alginate. Results show that the combination
of cell microencapsulation and microcarrier technology is an
optimum process for the scalable production and storage of high-
quality pluripotent hESCs.
Microencapsulation in alginate proved valuable for improving
hESC expansion in stirred tank bioreactors, since it ensures a
shear stress free microenvironment and avoids excessive clustering
of microcarriers or aggregates in culture. This strategy is extremely
attractive for use in large-scale bioprocesses, enabling tighter
control of the culture and higher cell expansion yields than non-
encapsulated cultures.
Our results show that the microencapsulation of hESCs
immobilized on microcarriers is also very efficient strategy for
the long-term culture of undifferentiated cells, overcoming the
limitations of both single cells and aggregate cultures. Cell-cell and
cell-matrix interactions significantly affect stem cell fate decisions
(apoptosis, self-renewal, differentiation) (reviewed in [3,33]). Our
results are in agreement, showing that these interactions lead to
improved stem cell bioprocesses. In fact, hESCs drastically lose
their viability when encapsulated as single cells, even after
treatment with Y-27632, a selective ROCK inhibitor known to
prevent apoptosis of hESCs after single cell enzymatic dissociation
[31,34]. When encapsulated as aggregates, hESCs tend to
spontaneously differentiate after 2 weeks of culture; this might
be explained by the observed increase in aggregate size
(.250 mm), which may limit the diffusion of growth factors and
gas substrates within aggregates, thereby inducing the formation of
EB-like structures and reducing cell proliferation capacity. In a
previous study, Siti-Ismai et al. reported the long-term feeder-free
cultivation of hESC aggregates in large (approximately 1 mm)
calcium alginate capsules, confirming that cells retained their
undifferentiated state and pluripotent characteristics for up to 260
days [12]. This difference in cell behavior may reflect the distinct
hESC line and/or culture conditions (alginate matrix, culture
medium) used. Nevertheless, the culture of microencapsulated
hESC aggregates could be adopted for the production of human
stem cell derivatives, by inducing directed differentiation at the
second week of culture (when stem cell population is still
pluripotent) and bypassing the EB formation step in a controlled
manner. There are several studies reporting the use of this strategy
to differentiate mouse and/or human ESCs into pancreatic
insulin-producing cells [28], hepatocytes [26] definitive endoderm
[31], cardiomyocytes [25] and osteoblasts [24]. High expectations
are raised by these culture strategies to potentiate the use of hESCs
in cell therapy and tissue engineering applications (reviewed in
[35]).
Another advantage of microcarrier technology in stem cell
expansion processes is the flexibility with which the area available
for cell growth can be adjusted, further facilitating the process
Table 2. Characteristics and bioprocess yields of the 3D strategy and the standard 2D protocols.
2D Strategy
(colonies culture)
3D Strategy
(microencapsulated cells-microcarriers)
Culture system
Adherent, Static
(well plates, Petri dishes)
Suspension, Stirred
(Stirred tank bioreactors, spinner vessels)
Ease of monitorization Yes Yes
Ease of handling Yes Yes
Ease of scale-up No Yes
Time- and space- consuming Yes No
Reproducibility Low High
Mimicry stem cells’ native microenvironment No Yes
Affordability Yes costs associated to encapsulation equipment/process and
material (microcarriers, hydrogels)
Expansion ratios 11
[7] 20
Maximum Cell Concentration (610
6 cell/mL) 0.2
[7] 3
Cell survival after cryopreservation (slow freezing rate) ,20%
[5] .70%
doi:10.1371/journal.pone.0023212.t002
Figure 5. Post-thawing characterization of encapsulated hESCs immobilized on microcarriers. Phenotype analysis of encapsulated hESC
immobilized on Matrigel coated Cytodex3 microcarriers (A) 9 days post-thawing (P0) and (B) after 2 and 5 cell passages in 2D culture systems (P2 and
P5, respectively); confocal images of Oct-4, and TRA-1-60 labeling and phase contrast pictures of alkaline phosphatase (AP) activity. Nuclei were
labeled with DAPI (blue). Scale bars: (A) 100 mm and (B) 200 mm for immunofluorescence images; (A, B) 1 mm for phase contrast images. (C) Flow
cytometry analysis; percentage of SSEA-4, hES-Cellect
TM (hES) and SSEA-1 positive cells after 2 and 5 cell passages post-thawing (P2 and P5,
respectively). Error bars represent SD of 2 measurements. (D) In vitro pluripotency analysis. Microcapsules were dissolved and hESCs were detached
from the microcarriers and transferred to a monolayer of inactivated hFF. At confluence, colonies were dissociated and hESCs were able to form
embryoid bodies (EBs) in non-adherent conditions and differentiated into cells from all three germ layers. Fluorescence images of differentiated
cultures labeled for a–SMA (a smooth muscle actin, mesoderm), FOX-A2 (Forkheadbox A2, endoderm) and bIII-Tub (b tubulin type III, ectoderm).
Nuclei were stained with DAPI (blue). Scale bars: 100 mm.
doi:10.1371/journal.pone.0023212.g005
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scalability would have tremendous impact in reducing the costs
of cell manufacturing by cutting the media, growth factors and
other expensive supplements needed for stem cell cultivation [36].
Increasing the concentration of microcarriers permitted us to
reach up to 3610
6 cell/mL, corresponding to a 15-fold increase in
final cell yields when compared to standard 2D protocols [7]
(Table 2). Although performed in small lab scale spinner vessels,
the strategies developed hereby can be easily up-scaled to
environmentally controlled stirred tank bioreactors where scal-
ability, automation and accurate control of culture environment
are guaranteed; our group has recently shown that the expansion
of pluripotent hESCs can be further improved in stirred tank
bioreactors with controlled pO2 and continuous perfusion [7].
This study further established that microencapsulation of
hESCs immobilized on microcarriers is an efficient process for
the cryopreservation of hESCs, since it allows for the recovery of
undifferentiated hESCs with high viabilities and the maintenance
of their pluripotent characteristics over several passages under
standard culture conditions, enabling their use for further
applications. The presence of components of the extracellular
matrix on microcarrier cultures (e.g. collagen, laminin) may
contribute to enhance cell survival during freezing and thawing
[37,38], by reducing post-thaw apoptosis [5,37]. In contrast,
microencapsulated aggregates showed high cell death immediately
after thawing. The limitations in heat and mass (water and
cryoprotectant) transfer within the aggregates may result in
different cryoprotection gradients, possibly leading to cryodamage
[30,39]. More fundamental studies on the physico-chemical and
biophysical phenomena occurring during freezing/thawing of
microencapsulated hESC aggregates should allow for further
improvement of this process.
It is important to highlight that the cryopreservation of hESCs
immobilized on microcarriers has already been reported by Nie
et al [10]. The key advantage of our strategy is that higher cell
recovery yields can be achieved without the use of feeder cells. The
alginate microcapsule allows further improvement of post-thaw
cell viability, enhancing up to a 3-fold boost in cell survival
compared to non-encapsulated cultures. Although the underlying
mechanisms are still unclear, several studies indicate that
maintaining cell-cell/matrix contacts improves hESC recovery
following cryopreservation [37,40]. Cell entrapment within
alginate microcapsules may help protect hESCs from the adverse
effects of cryopreservation, not only by preventing the disruption
of cell-cell and cell-matrix contacts [21,30] but also by decreasing
exposure to cryoprotectants and preventing the damage caused by
intracellular ice formation and propagation (via gap junctions)
[41].
This is the first time that the successful expansion and
cryopreservation of pluripotent hESCs on microcarriers inside
alginate microcapsules have been reported. Moreover, an
integrated bioprocess for the efficient production, banking and
distribution of hESCs in a scalable and straightforward manner is
now possible. The main limitations of this 3D strategy, when
compared to the standard 2D protocols, are the costs associated
with the encapsulation equipment/process and material (micro-
carriers and alginate) (Table 2). But its inherent scalability and
reproducibility and the high bioprocess yields associated with the
3D approach (Table 2) should more than compensate. Hopefully,
the integrated strategy developed herein will potentiate hESCs to
achieve a wider range of applications. As hESCs can be harvested
from the microcapsules with high viability and pluripotency, they
could have immediate use for in vitro applications demanding high
numbers of cells, e.g. in high-throughput screening of pharma-
ceutical compounds. However, from a clinical perspective, further
improvements are still required including the adaptation to
defined xeno-free culture conditions and the integration of a
directed differentiation step. The presence of microcarriers within
the microcapsules is still a concern, requiring an additional step to
release cells from the microcapsules and separate them from the
microcarriers before cell transplantation; alternatively, a biode-
gradable, clinically approved microcarrier could be used. Indeed,
gelatin and pharmacologically active microcarriers (PAMs) have
been used successfully in adult cell therapy for brain neuronal
damage and cartilage engineering (reviewed in [42]). Although the
type of alginate used in this study has never been tested in clinical
studies, it is manufactured in compliance with current GMP and
presents low levels of endotoxins (#100 EU/g), conditions that
may boost its use in transplantation experiments.
In conclusion, the experiments herein described demonstrate
that cell microencapsulation in alginate is a powerful tool for
integrating expansion and cryopreservation of pluripotent hESCs.
Moreover, the combination of cell microencapsulation with
microcarrier technology promotes cellular interactions that are
essential for improved production and storage of hESCs without
compromising their viability, self-renewal and pluripotency. This
3D culture strategy represents an important step for enlarging the
range of hESC applications for regenerative medicine, tissue
engineering and in vitro toxicology. Future studies will incorporate
a differentiation step so as to develop a fully integrated bioprocess
for the expansion, differentiation and storage of clinically relevant
hESC derivatives.
Supporting Information
Figure S1 Microencapsulation of hESCs as single cells
in alginate. Phase contrast and fluorescence images of hESC
encapsulated at 26106 cell/mL alginate, by day 1 (A) and day 7
(B) of culture. Viability analysis of cultures stained with
fluoresceine diacetate (FDA-live cells, green) and propidium iodide
(PI- dead cells, red). Scale bar: 200 mm.
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